EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Outcomes With Notch Inhibitors in Notch‐Activated Recurrent/Metastatic Adenoid Cystic Carcinoma

Camilla O Hoff, Luana G de Sousa iD, Flavia Bonini iD, Eduardo Dal Lago, Kaiwen Wang, Juliana M Siqueira, Yoshitsugu Mitani iD, Adel K El-Naggar, Renata Ferrarotto iD

Cancer Medicine · 2025-03 · 14 (5)

DOI: 10.1002/cam4.70663 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 02.03.2025. Verfasst von Camilla O Hoff und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Carcinoma, Adenoid Cystic, Neoplasm Recurrence, Local, Receptor, Notch1, Receptors, Notch. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adenoid cystic carcinoma (ACC) with NOTCH‐activating mutations presents a clinical challenge due to its poor prognosis. NOTCH inhibitors have emerged as a potential therapy for ACC patients with NOTCH activation. This study aimed to evaluate the efficacy of NOTCH inhibitors in this patient population.

Methods

A retrospective analysis was conducted on patients with metastatic ACC harboring NOTCH pathway activation, who received NOTCH inhibitors at MD Anderson Cancer Center. NOTCH inhibitors included AL101, a gamma‐secretase inhibitor, and brontictuzumab, an antibody targeting NOTCH1. NOTCH pathway activation was assessed through genomic analysis for NOTCH‐activating mutations or immunohistochemistry for NOTCH1 intracellular domain (NICD1). Efficacy endpoints included best overall response (BOR) and progression‐free survival (PFS) per RECIST or MD Anderson bone response criteria.

Results

Twenty‐nine patients were included, with a predominance of solid histology (86%). NOTCH‐activating mutations were identified in 82% of patients, and 95% showed positive NICD1 staining. BOR revealed partial response in 17% of patients, stable disease in 55%, and progressive disease in 28%. Median response duration was longer for AL101 compared to brontictuzumab (9.9 vs. 1.7 months, p = 0.04). Median PFS with NOTCH inhibitor was 4.2 months (95% CI 2.7–8.6 months). Progression of nontarget lesions occurred in 34% of patients. Comparison with prior therapy showed longer PFS with NOTCH inhibitors (HR 0.38, 95% CI 0.19–0.78, p = 0.0065).

Conclusion

NOTCH inhibitors demonstrate activity in NOTCH‐activated ACC, surpassing the efficacy of observation or prior systemic therapies. However, limited PFS and progression of nontarget lesions suggest the potential need for combination therapy to address ACC heterogeneity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Adenoid CysticNeoplasm Recurrence, LocalReceptor, Notch1Receptors, NotchHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultMutationTreatment OutcomeAntibodies, Monoclonal, HumanizedAmyloid Precursor Protein SecretasesProgression-Free Survival

Substanzen

Receptor, Notch1NOTCH1 protein, humanReceptors, NotchAntibodies, Monoclonal, HumanizedAmyloid Precursor Protein Secretases

Autor:innen und Institutionen

  • Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.
  • Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Stomatology, Discipline of Oral and Maxillofacial Pathology, School of Dentistry, University of Sao Paulo, Sao Paulo, Brazil.
  • Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Luana G de Sousa, Flavia Bonini, Yoshitsugu Mitani, Renata Ferrarotto

Förderung

  • NCI NIH HHS

Zitieren

APA

Hoff, C. O., de Sousa, L. G., Bonini, F., Lago, E. D., Wang, K., Siqueira, J. M., Mitani, Y., El-Naggar, A. K., & Ferrarotto, R. (2025). Clinical Outcomes With Notch Inhibitors in Notch‐Activated Recurrent/Metastatic Adenoid Cystic Carcinoma. Cancer Medicine, 14(5). https://doi.org/10.1002/cam4.70663

Vancouver

Hoff CO, de Sousa LG, Bonini F, Lago ED, Wang K, Siqueira JM, et al. Clinical Outcomes With Notch Inhibitors in Notch‐Activated Recurrent/Metastatic Adenoid Cystic Carcinoma. Cancer Medicine. 2025;14(5). doi:10.1002/cam4.70663

BibTeX
@article{Hoff2025,
  author = {Hoff, Camilla O and de Sousa, Luana G and Bonini, Flavia and Lago, Eduardo Dal and Wang, Kaiwen and Siqueira, Juliana M and Mitani, Yoshitsugu and El-Naggar, Adel K and Ferrarotto, Renata},
  title = {Clinical Outcomes With Notch Inhibitors in Notch‐Activated Recurrent/Metastatic Adenoid Cystic Carcinoma},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {5},
  doi = {10.1002/cam4.70663}
}
Kostenlos starten →